Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSB202 in Relapsed/Refractory Indolent B-Cell Malignancies
NCT05003141Phase 1Unknown
- Sponsor
- Qilu Puget Sound Biotherapeutics
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of PSB202 in follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 4 more, sponsored by Qilu Puget Sound Biotherapeutics. Primary endpoints: Adverse Events up to 27 weeks and Dose Limiting Toxicity at 3 weeks. Status: unknown.
02
Drugs
PSB202
03
Conditions
follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Waldenstrom macroglobulinemia (WM)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05003141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003141.